DYN Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of -- compared to Dyne Therapeutics's net margin of 16.9%. Dyne Therapeutics's return on equity of -- beat Corcept Therapeutics's return on equity of 23.78%.

Dyne Therapeutics has a consensus price target of $47.86, signalling upside risk potential of 540.66%. On the other hand Corcept Therapeutics has an analysts' consensus of $143.25 which suggests that it could grow by 112.44%. Given that Dyne Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Dyne Therapeutics is more attractive than Corcept Therapeutics.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.145, suggesting its less volatile than the S&P 500 by 85.456%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Corcept Therapeutics quarterly revenues of $181.9M. Dyne Therapeutics's net income of -$89.5M is lower than Corcept Therapeutics's net income of $30.7M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Corcept Therapeutics's PE ratio is 54.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 11.34x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of -- compared to Dyne Therapeutics's net margin of 23.56%. Dyne Therapeutics's return on equity of -- beat Gilead Sciences's return on equity of 2.5%.

Dyne Therapeutics has a consensus price target of $47.86, signalling upside risk potential of 540.66%. On the other hand Gilead Sciences has an analysts' consensus of $112.50 which suggests that it could grow by 5.64%. Given that Dyne Therapeutics has higher upside potential than Gilead Sciences, analysts believe Dyne Therapeutics is more attractive than Gilead Sciences.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.91% to investors and pays a quarterly dividend of $0.79 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Gilead Sciences quarterly revenues of $7.6B. Dyne Therapeutics's net income of -$89.5M is lower than Gilead Sciences's net income of $1.8B. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 287.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 4.66x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -- compared to Dyne Therapeutics's net margin of 24.89%. Dyne Therapeutics's return on equity of -- beat Nektar Therapeutics's return on equity of -133.07%.

Dyne Therapeutics has a consensus price target of $47.86, signalling upside risk potential of 540.66%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 714.15%. Given that Nektar Therapeutics has higher upside potential than Dyne Therapeutics, analysts believe Nektar Therapeutics is more attractive than Dyne Therapeutics.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.381%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Nektar Therapeutics quarterly revenues of $29.2M. Dyne Therapeutics's net income of -$89.5M is lower than Nektar Therapeutics's net income of $7.3M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 1.26x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Avidity Biosciences has a net margin of -- compared to Dyne Therapeutics's net margin of -3439.52%. Dyne Therapeutics's return on equity of -- beat Avidity Biosciences's return on equity of -29.4%.

Dyne Therapeutics has a consensus price target of $47.86, signalling upside risk potential of 540.66%. On the other hand Avidity Biosciences has an analysts' consensus of $66.69 which suggests that it could grow by 147.84%. Given that Dyne Therapeutics has higher upside potential than Avidity Biosciences, analysts believe Dyne Therapeutics is more attractive than Avidity Biosciences.

Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Avidity Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Avidity Biosciences pays out -- of its earnings as a dividend.

Dyne Therapeutics quarterly revenues are --, which are smaller than Avidity Biosciences quarterly revenues of $3M. Dyne Therapeutics's net income of -$89.5M is higher than Avidity Biosciences's net income of -$102.3M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Avidity Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 275.43x for Avidity Biosciences. Usually stocks with elevated PS ratios are considered overvalued.